Back
Nuveen NASDAQ 100 Dynamic Overwrite Fund Vs. Madrigal Pharmaceuticals Industry Stock Comparison
Buy
63
QQQX
Nuveen NASDAQ 100 Dynamic Overwrite Fund
Last Price:
25.18
Seasonality Move:
-0.32%
Buy
82
MDGL
Madrigal Pharmaceuticals
Last Price:
320.26
Seasonality Move:
31.67%
Buy
63
Nuveen NASDAQ 100 Dynamic Overwrite Fund (QQQX)
is a Buy
Is Nuveen NASDAQ 100 Dynamic Overwrite Fund a Buy, Sell or Hold?
- The current Nuveen NASDAQ 100 Dynamic Overwrite Fund [QQQX] share price is $25.19. The Score for QQQX is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.
- QQQX is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Buy
82
Madrigal Pharmaceuticals (MDGL)
is a Buy
Is Madrigal Pharmaceuticals a Buy, Sell or Hold?
- The current Madrigal Pharmaceuticals [MDGL] share price is $319.58. The Score for MDGL is 82, which is 64% above its historic median score of 50, and infers lower risk than normal.
- MDGL is currently trading in the 80-90% percentile range relative to its historical Stock Score levels.
- This Score is currently showing an extreme reading that indicates risk levels may be considerably lower than normal.
QQQX Stock Price Chart
What is Nuveen NASDAQ 100 Dynamic Overwrite Fund's stock price today?
-
The Nuveen NASDAQ 100 Dynamic Overwrite Fund share price today is $25.19
The current trend is moderately bearish and QQQX is experiencing slight selling pressure.
MDGL Stock Price Chart
What is Madrigal Pharmaceuticals's stock price today?
-
The Madrigal Pharmaceuticals share price today is $319.58
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and MDGL is experiencing buying pressure, which is a positive indicator for future bullish movement.
QQQX Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.12 | Buy |
| Relative Strength Index (14 RSI): | 50.05 | Buy |
| Chaikin Money Flow: | -11740 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (25.05 - 25.41) | Sell |
| Bollinger Bands (100): | (24.22 - 25.34) | Buy |
MDGL Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 8.37 | Buy |
| Relative Strength Index (14 RSI): | 85.5 | Buy |
| Chaikin Money Flow: | 2945933 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (194.64 - 241.02) | Buy |
| Bollinger Bands (100): | (221.59 - 279.03) | Buy |
QQQX Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 25.35 | Sell |
| 20-day SMA: | 25.28 | Sell |
| 50-day SMA: | 24.92 | Buy |
| 200-day SMA: | 24.21 | Buy |
| 8-day EMA: | 25.33 | Sell |
| 20-day EMA: | 25.25 | Sell |
| 50-day EMA: | 25.01 | Buy |
| 200-day EMA: | 24.33 | Buy |
MDGL Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 230.72 | Buy |
| 20-day SMA: | 219.8 | Buy |
| 50-day SMA: | 228.31 | Buy |
| 200-day SMA: | 241.11 | Buy |
| 8-day EMA: | 244.62 | Buy |
| 20-day EMA: | 228.06 | Buy |
| 50-day EMA: | 230.04 | Buy |
| 200-day EMA: | 234.49 | Buy |
Nuveen NASDAQ 100 Dynamic Overwrite Fund Earnings Growth & QQQX Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Madrigal Pharmaceuticals Earnings Growth & MDGL Earnings Dates
- Analysts estimate an earnings decrease this quarter of $3.75 per share, a decrease next quarter of $0.00 per share, a decrease this year of $4.12 per share, and an increase next year of $8.67 per share.
Nuveen NASDAQ 100 Dynamic Overwrite Fund Technical Analysis
| Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 21 | 22 | 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Madrigal Pharmaceuticals Technical Analysis
| Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 21 | 22 | 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||